



NDA 015923/S-092  
NDA 018701/S-070

**SUPPLEMENT APPROVAL**

Janssen Pharmaceuticals, Inc.  
Attention: Mary Mulligan  
Associate Director, Global Regulatory Affairs  
920 U.S. Highway 202, P.O. Box 300  
Raritan, NJ 08869-0602

Dear Ms. Mulligan:

Please refer to your Supplemental New Drug Applications (sNDA) dated and received October 28, 2014, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for NDA 015923 Haldol (haloperidol) Injection (for immediate release) 5 mg/ml and NDA 018701 Haldol (haloperidol decanoate) Intramuscular Injection 50 mg/ml and 100 mg/ml.

We acknowledge receipt of your amendment dated October 10, 2017, which constituted a complete response to our September 19, 2016, action letter.

These Prior Approval supplemental new drug applications provide for revisions to the Warnings & Adverse Reactions sections based upon your Company Core Data Sheet.

**APPROVAL & LABELING**

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

We note that your November 20, 2017, submission includes final printed labeling (FPL) for your package insert. We have not reviewed this FPL. You are responsible for assuring that the wording in this printed labeling is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at

<http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your applications, you are exempt from this requirement.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

NDA 015923/S-092  
NDA 018701/S-070

Page 3

If you have any questions, please email Simran Parihar, PharmD, at [simran.parihar@fda.hhs.gov](mailto:simran.parihar@fda.hhs.gov).

Sincerely,

*{See appended electronic signature page}*

Mitchell V. Mathis, MD  
Division Director  
Division of Psychiatry Products  
Office of Drug Evaluation I  
Center for Drug Evaluation and Research

ENCLOSURE:  
Content of Labeling